Skip to main content

Advertisement

SpringerLink
Log in

Review Update on Topical Therapy for Psoriasis

  • Psoriasis (Jaishin Wu, Section Editor)
  • Published:
Current Dermatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Studies show frequent usage but low adherence rates and poor satisfaction from topical therapy for psoriasis. These were attributed to low efficacy, inconvenience of application, and poor cosmetic quality for different body parts.

Recent Findings

Multicenter surveys on patients suggest a two-way holistic approach, where patients convey what bothers them most and doctors explain how products address specific concerns. New rapid response targeted topical agents, in cosmetically acceptable preparations, applied less often, are undergoing efficacy and safety studies, ideally on large populations up to 1 year or more. Until available, this review addresses gaps in knowledge on how to maximize effects of emollients, used alone, with physiologic lipids, or as base for active topical therapy.

Summary

Updates—on how psoriasis skin becomes itchy, red, dry, thick, and scaly from inflammation and barrier defects—explain clinical responses to the physical, chemical, and functional properties of psoriasis topical therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643–59. https://doi.org/10.1016/j.jaad.2008.12.032.

    Article  PubMed  Google Scholar 

  2. Assessment and management of psoriasis: NICE Clinical Guideline by the National Clinical Guidelines Centre at the Royal College of Physicians Oct 2012; pp 210–374.

  3. van de Kerkhof PC, Reich K, Kavanaugh A, Bachelez H, Barker J, Girolomoni G, et al. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Eur Acad Dermatol Venereol. 2015;29(10):2002–10. https://doi.org/10.1111/jdv.13150.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Vaidya TS, Alikhan A. Treatment satisfaction among patients with psoriasis at a large academic center: an observational study. [Published online ahead of print September 27, 2016]. J Dermatol Treat https://doi.org/10.1080/09546634.2016.1240865.

  5. Finch T, Shim TN, Roberts L, Johnston O. Treatment satisfaction among patients with moderate-to-severe. J Clin Aesthet Dermatol. 2015;8(4):26–30.

    PubMed  PubMed Central  Google Scholar 

  6. • Oda DC, de Korte J, Sprangers MAG, de Rie M, Smets EMA. Satisfaction with treatment among patients with psoriasis: a web-based survey study. Brit J Dermal. 2013;169(2). An excellent study on patient satisfaction.

  7. •• Alinia H, Moradi TS, Smith JA, et al. Long term adherence to topical psoriasis treatment can be abysmal: a 1-year randomised intervention study using objective electronic adherence monitoring. Br J Dermatol. 2017;176(3):759–64. https://doi.org/10.1111/bjd.15085. A unique methodology lasting one year on patient adherence.

    Article  CAS  PubMed  Google Scholar 

  8. •• Feldman SR, Goffe B, Rice G, Mitchell M, Kaur M, Roberson D, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. An Health Drug Benefits. 2016;9(9):504–13. A U.S. multicenter study that underscores why holistic management is needed.

    Google Scholar 

  9. •• Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871–81. https://doi.org/10.1016/j.jaad.2013.12.018. A multi-country survey also underscoring why holistic management is needed.

    Article  PubMed  Google Scholar 

  10. •• Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physical results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Am J Clin Dermatol. 2016;17(1):87–97. https://doi.org/10.1007/s40257-015-0169-x. The US perspective on the same subject.

    Article  PubMed  Google Scholar 

  11. •• Wu JJ, Lynde CW, Kleyn CE, Iversen L, van der Walt JM, Carvalho A, et al. Identification of key research needs for topical therapy treatment of psoriasis-a consensus paper by the International Psoriasis Council. J Eur Acad Dermatol Venereol. 2016;30(7):1115–9. https://doi.org/10.1111/jdv.13614. More on the same subject of holistic management underscoring its importance.

    Article  CAS  PubMed  Google Scholar 

  12. Thaci D, Augustin M, Krutmann J, Luget T. Importance of basic therapy in psoriasis. J Dtsch Dermatol Ges. 2015;13(5):415–8. https://doi.org/10.1111/ddg.12615.

    PubMed  Google Scholar 

  13. Torsekar R, Gautam MM. Topical therapies in psoriasis. Indian Dermatol Online J. 2017;8(4):235–45. https://doi.org/10.4103/2229-5178.209622. Review

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Vasilopoulos Y, Walters K, Cork MJ, Duff GW, Sagoo GS, Tazi-Ahnini R. Association analysis of the skin barrier gene cystatin a at the PSORS5 locus in psoriatic patients: evidence for interaction between PSORS1 and PSORS5. Eur J Hum Genet. 2008;16(8):1002–9. https://doi.org/10.1038/ejhg.2008.40.

    Article  CAS  PubMed  Google Scholar 

  15. Huffmeier U, Bergboer JG, Becker T, et al. Replication of LCE3C-LCE3B CNV as a risk factor for psoriasis and analysis of interaction with other genetic risk factors. J Invest Dermatol. 2010;130(4):979–84. https://doi.org/10.1038/jid.2009.385.

    Article  PubMed  Google Scholar 

  16. Riveira-Munoz E, He SM, Escaramis G, et al. Meta-analysis confirms the LCE3C and LCE3B deletion as a risk factor for psoriasis in several ethnic groups and finds interaction with HLA-Cw6. J Invest Dermatol. 2011;131(5):1105–9. https://doi.org/10.1038/jid.2010.350.

    Article  CAS  PubMed  Google Scholar 

  17. Zhang XJ, Huang W, Yang S, Sun LD, Zhang FY, Zhu QX, et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet. 2009;41(2):205–10. https://doi.org/10.1038/ng.310.

    Article  CAS  PubMed  Google Scholar 

  18. Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. 2010;42(11):985–90. https://doi.org/10.1038/ng.694.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Okada Y, Han B, Tsoi LC, Stuart PE, Ellinghaus E, Tejasvi T, et al. Fine mapping major histocaompatibility complex associations in psoriasis and its clinical subtypes. Am J Hum Genet. 2014;95(2):162–72. https://doi.org/10.1016/j.ajhg.2014.07.002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Yin X, Low HQ, Wang L, Li Y, Ellinghaus E, Han J, et al. Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility. Nat Commun. 2015;6:6916. https://doi.org/10.1038/ncomms7916.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. •• Puig L, Julia A, Marsai S. The pathogenesis and genetics of psoriasis. Actas Dermosifiliogr. 2014;105(6):535–45. https://doi.org/10.1016/j.ad.2012.11.006. New findings on psoriasis genesis in regards to the skin barrier.

    Article  CAS  PubMed  Google Scholar 

  22. •• Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review. J Autoimmun. 2015;64:66–73. https://doi.org/10.1016/j.jaut.2015.07.008. An excellent immuno-pathogenetic model of psoriasis.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. •• Stawczyk-Macieja M, Aneta Szczerkowska-Dobosz A, Rębała K, Dorota Purzycka-Bohdan D. Genetic background of skin barrier dysfunction in the pathogenesis of psoriasis vulgaris. Postepy Dermatol Alergol. 2015; XXXII;2(2):123–6. https://doi.org/10.5114/pdia.2014.44003. Recent study on the barrier in psoriasis.

  24. •• Ye L, Lv C, Man G, Song S, Elias PM, Man M-Q. Abnormal epidermal barrier recovery in uninvolved skin supports the notion of an epidermal pathogenesis of psoriasis. J Invest Dermatol. 2014;134(11):2843–6. https://doi.org/10.1038/jid.2014.205. A good clinical translation of the basic studies done on the barrier in psoriasis.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. •• Wooi NK, Lau WM. Skin deep: the basics of human skin structure and drug penetration. In: Dragicevie N, Maibach HI, editors. Percutaneous penetration enhancers chemical methods in penetration enhancement: drug manipulation strategies and vehicle effects. Springer: Berlin; 2015. p. 3–11. An excellent basis for understanding natural oils and their effects on the skin.

    Google Scholar 

  26. Verallo-Rowell VM, Katalbas SS, Pangasinan JP. Natural (mineral, vegetable, coconut, essential) oils and contact dermatitis. Curr Allergy Asthma Rep. 2016;16(7):51. https://doi.org/10.1007/s11882-016-0639-9.

    Article  PubMed  Google Scholar 

  27. Ali B, Al-Wabel NA, Shams S, Abamad A, Khan AS, Anwar F. Review article essential oils used in aromatherapy: a systematic review. Asian Packag J Trop Biomed. 2015;5(8):601–11. https://doi.org/10.1016/j.apjtb.2015.05.007.

    Article  Google Scholar 

  28. de Groot AC, Schmidt E. Review essential oils, part I: introduction. Dermatitis. 2016;27(2):39–42. https://doi.org/10.1097/DER.0000000000000175.

    Article  PubMed  Google Scholar 

  29. Rawlings AV, Lombard KJ. A review on the extensive skin benefits of mineral oil. Int J Cosmet Sci. 2012:34–511.

  30. •• Enig MG. Know your fats: the complete primer for understanding the nutrition of fats, oils, and cholesterol .Chapter 4. The many sources of Fats and Oils. Bethesda Press; 2002. pp 113–152. Basic and Simple on the chemistry of fats.

  31. Fluhr JW, Darlensi R, Surber C. Glycerol and the skin holistic approach to its origin and functions. Br J Dermatol. 2008;159(1):23–4. https://doi.org/10.1111/j.1365-2133.2008.08643.x.

    Article  CAS  PubMed  Google Scholar 

  32. Verallo-Rowell VM. Rx: Coconuts! (The Perfect Health Nut), XLibris Philadelphia. 2005;25–90.

  33. • Mack Correa CM, Mao G, Saad P, Flach CR, Mendelsohn R, Walters RM. Molecular interactions of plant oil components with stratum corneum lipids correlate with clinical measures of skin barrier function. Exp Dermatol. 2014;23(1):39–4. https://doi.org/10.1111/exd.12296. A study on how natural oils become incorporated into the epidermal cells.

    Article  CAS  PubMed  Google Scholar 

  34. Madison KC, Howard EJ. Ceramides are transported through the Golgi apparatus in human keratinocytes in vitro. J Invest Dermatol. 1996;106(5):1030–5. https://doi.org/10.1111/1523-1747.ep12338596.

    Article  CAS  PubMed  Google Scholar 

  35. Schroeter A, Eichener A, Mueller J, Neubert RHH. The importance of stratum corneum lipid organization for proper barrier function, in Percutaneous Penetration Enhancers Chemical methods in penetration enhancement. Drug manipulation strategies and vehicle effects. Eds Dragicevic N, Maibach HI. 2015;19–38.

  36. Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetrate of chemical compounds and drugs. Exp Dermatol. 2000;9(30):165–9. https://doi.org/10.1034/j.1600-0625.2000.009003165.x.

    Article  CAS  PubMed  Google Scholar 

  37. Hussain A, Singh S, Sharma D, Webster TJ, Shafaat K, Faruk A. Elastic liposomes as novel carriers: recent advances in drug delivery. Int J Nanomedicine. 2017;12:087–5108.

    Article  Google Scholar 

  38. Kumar PKP, Krishna AGG. Physicochemical characteristics of commercial coconut oils produced in India. Grass Y Aceites. 2015;66(1):e062ISSN-L:0017–3495.

  39. Anastopoulous G, Zannikou Y, Stournas S, Kalligeros S. Transesterification of vegetable oils with ethanol and characterisation of the key fuel properties of ethyl esters. Energies. 2009;2(2):362–76. https://doi.org/10.3390/en20200362.

    Article  Google Scholar 

  40. •• Mahil SK, Capon F, Barker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016;38(1):11–27. https://doi.org/10.1007/s00281-015-0539-8. New and well written on therapy based on immunopathogenesis.

    Article  CAS  PubMed  Google Scholar 

  41. Ali SM, Yosipovitch G. Skin pH: from basic science to basic skin care. Acta Dermatol Venereol. 2013;93(3):261–7. https://doi.org/10.2340/00015555-1531.

    Article  Google Scholar 

  42. Serafini A. Beitrag zum experimentellen Studium der Desinfectionsfahigkeit gewohnlichseifen. Arch Hyg. 1898;33:369–98.

    Google Scholar 

  43. Konradi D. Uber die bactericide Wirkung der Seifen. Arch Hyg. 1902;44:101–12.

    Google Scholar 

  44. Reichenbach H. Die desinfizierenden Berstandteile der Seifen. Zeitschr Hyg. 1908;9:296–316.

    Google Scholar 

  45. Ferri M, Ranucci E, Romagnoli P, Giaconni V. Antimicrobial resistance: a global emerging threat to public health systems. Crit Rev Food Sci Nutr. 2017;57(13):2857–76. https://doi.org/10.1080/10408398.2015.1077192.

    Article  CAS  PubMed  Google Scholar 

  46. Kabara JJ, Swieczkowski DM, Conley AJ, Truant JP. Fatty acids and derivatives as antimicrobial agents. Antimicrob Agents Chemother. 1971;2:23–8.

    Article  Google Scholar 

  47. •• Thormar H, Hilmarsson H, Bergsson G. Antimicrobial lipids: role in innate immunity and potential use in prevention and treatment of infections. In: Méndez-Vilas A, editor. Microbial pathogens and strategies for combating them: science, technology and education, vol. 3. Badajoz: Formatex Research Center; 2013. p. 1474–88. This is an important information source on the antimicrobial effects of natural oils.

    Google Scholar 

  48. Desbois AP, Smith VJ. Antibacterial free fatty acids: activities, mechanisms of action and biotechnological potential. Appl Microb Biotechnol. 2010;85(6):1629–42. https://doi.org/10.1007/s00253-009-2355-3.

    Article  CAS  Google Scholar 

  49. Heerklotz H. Interactions of surfactants with lipid membranes. Q Rev Biophys. 2008;41(3-4):205–64. https://doi.org/10.1017/S0033583508004721.

    Article  CAS  PubMed  Google Scholar 

  50. Hammer KA, Carson CF. Antibacterial and antifungal activities of essential oils. In: Lipids and Essential oils as antimicrobial agents. Hoboken: John Wiley & Sons, Ltd; 2011. p. 255–306.

    Google Scholar 

  51. • Jackman JA, Yoon BK, Li D, Cho NJ. Nanotechnology formulations for antibacterial free fatty acids and monoglycerides. Molecules. 2016;21(3):305. https://doi.org/10.3390/molecules21030305. New and very futuristic uses for lipids.

    Article  PubMed  Google Scholar 

  52. • Szepietowski JC, Reich A. Mini review pruritus in psoriasis: an update. E J Pain. 2015;20(1):41–6. https://doi.org/10.1002/ejp.768. New studies on neurogenic basis for the itching in psoriasis.

  53. •• Norlén L. Molecular structure and function of the skin barrier. In: Dragicevic N, Maibach HI, editors. Percutaneous penetration enhancers chemical methods in penetration enhancement: drug manipulation strategies and vehicle effects. Berlin: Springer; 2015. p. 39–42. This continues with more basic knowledge about the barrier layer of the skin as background to understanding natural oils and their effects on the barrier.

    Google Scholar 

  54. Roussel L, Abdayem R, Gilbert E, Pirot F, Haftek M. Influence of excipients on two elements of the stratum corneum barrier: intercellular lipids and epidermal tight junctions. In: Dragicevic N, Maibach HI, editors. Percutaneous penetration enhancers chemical methods in penetraten enhancement. Berlin: Springer; 2015. https://doi.org/10.1007/978-3-662-45013-0_7.

    Google Scholar 

  55. •• Calder PC. Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms, and clinical relevance. Biochem Biophys Acta. 2014. This continues the understanding of pro- and antiinflammatory effects of fatty acids derived from natural oils.

  56. Gomez C, Candela LM, Lopez B, Kohen VL. Importance of a balanced omega6/omega3 ratio for the maintenance of health. Nutritional recommendations. Nutr Hosp. 2011;26(2):323–9.

    Google Scholar 

  57. Baumann L. Olive oil Ch 14. In: Baumann L, editor. Cosmeceuticals and cosmetic ingredients. 1st ed. New York: McGraw-Hill; 2015. p. 37–40.

    Google Scholar 

  58. mvo.nl/media/voedselveiligheid/codex_standard_named_vegetable_oils.pdf . Accessed 6 Nov 2017.

  59. Librado AS, Von Luigi MV. Phenolic-dependent anti-lipid perioxidative, antimodulatory and antioxidant activity of VCO in vitro. Int Food Res J. 2013;20

  60. Carocho M, Ferreira IC. A review on antioxidants, prooxidants, and related controversy: natural and synthetic compounds, screening and analysis methodologies and future perspectives. Food Chem Toxicol. 2013;51:15–25. https://doi.org/10.1016/j.fct.2012.09.021.

    Article  CAS  PubMed  Google Scholar 

  61. •• del Rosso JQ. Moisturizer and barrier repair formulations. In: Draelos ZD, editor. Cosmeceuticals. 3rd ed. Amsterdam: Elsevier Inc; 2016. p. 81–90. Excellent summary of what’s out there.

    Google Scholar 

  62. •• Elias PM. Physiologic lipids for barrier repair in Ch 7. In: Draelos ZD, Dover JS, Alam M, editors. Cosmeceuticals. 3rd ed. Amsterdam: Elsevier; 2016. p. 49–54. This focuses on the lipids of the barrier and makes us understand how natural oils may be incorporated in it.

    Google Scholar 

  63. • Agero LA, Verallo-Rowell VM. A ramdomized double-blind controlled trial comparing extra virgin coconut oil with mineral oil as a moisturiser for mild to moderate xerosis. Dermatitis. 2004;15(3):109–16. https://doi.org/10.2310/6620.2004.04006. Our first study on coconut oil as a moisturiser.

    Article  PubMed  Google Scholar 

  64. • Escuadro MO, Maano MMC, Dofitas BL. A randomzied assessor blinded controlled trial on the efficacy and safety of virgin coconut oil versus mineral oil as a therapeutic moisturiser for senile xerosis. Poster Presentation published in Abstracts American Contact Dermatitis Society Annual Meeting 2013. A second study ten years later.

  65. • Evangelista MTP, Casintahan MFS, Villafuerte LL. The effect of topical virgin coconut oil on SCORAD index, transepidermal water loss and skin capacitance in mild to moderate pediatric atopic dermatitis: a randomized double-blind clinical trial. Int J Dermatol. 2014;53(1):100–8. https://doi.org/10.1111/ijd.12339.

    Article  PubMed  Google Scholar 

  66. Abraham ERL, Verallo-Rowell VM, Baello BQ. Testing of lauricidin vs. isopropyl alcohol for antisepsis of cutaneous hand microbes to prevent infection. Phil J Microbiol Infect Dis. 2000;29(3):12–135.

    Google Scholar 

  67. Abraham ERL, Verallo-Rowell VM. Safety and efficacy of monolaurin, a coconut extract vs. isopropyl alcohol in rinse-free hand antiseptic gels on MMC personnels hands and microbial isolates. J Phil Dermatol Soc. 2001;2:90–9.

    Google Scholar 

  68. Carpo BG, Verallo-Rowell VM, Kabara J. Novel antibacterial activity of monolaurin compared with converntional antibiotics against organisms from skin infections:an in-vitro study. J Drugs Dermatol. 2007;6(10):981–8.

    Google Scholar 

  69. Verallo-Rowell VM, Dillague KM, Sjah-Tjundawan BS. Novel antibacterial and emollient effects of coconut and virgin olive oils in adult atopic dermatitis. Dermatitis. 2008;19(6):308–15.

    PubMed  Google Scholar 

  70. Kim HO, Kim JH, Chung BY, Choi MG, Park CW. Increased expression of the aryl hydrocarbon receptor in patients with chronic inflammatory skin diseases. Exp Dermatol. 2014;23(4):278–81. https://doi.org/10.1111/exd.12350.

    Article  CAS  PubMed  Google Scholar 

  71. Arbiser JL, Govindarajan B, Battle TE, Lynch R, Frank DA, Ushio-Fukai M, et al. Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar. J Invest Dermatol. 2006;126(6):1396–402. https://doi.org/10.1038/sj.jid.5700276.

    Article  CAS  PubMed  Google Scholar 

  72. Khandpur S, Sahni K. An open label prospective randomized trial to compare the efficacy of coal tar salicylic acid ointment versus calcipotriol/betamethasone dipropionate ointment in the treatment of limited chronic plaque psoriasis. Indian J Dermatol. 2014;59:57983.

    Article  Google Scholar 

  73. Chiricozzi A, Pitocco R, Saraceno R, Nistico SP, Giunta A, Chimenti S. New topical treatments for psoriasis. Expert Opin Pharmacother. 2014;15(4):461–70. https://doi.org/10.1517/14656566.2014.875159.

    Article  CAS  PubMed  Google Scholar 

  74. Hollywood KA, Winder CL, Dunn WB, Xu Y, Broadhurst D, Griffiths CEM, et al. Exploring the mode of action of dithranol therapy for psoriasis: a metabolomic analysis using HaCaT cells. Mol BioSyst. 2015;11(8):2198–209. https://doi.org/10.1039/c4mb00739e.

    Article  CAS  PubMed  Google Scholar 

  75. Jacobi A, Mayer A, Augustin M. Keratolytics and emollients in the therapy of psoriasis. Dermatol Ther (Heidelb). 2015;5(1):1–18. https://doi.org/10.1007/s13555-015-0068-3.

    Article  Google Scholar 

  76. Uva L, Miguel D, Pinheiro C, Antunes J, Cruz D, Ferreira J, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:1–16. https://doi.org/10.1155/2012/561018.

    Article  Google Scholar 

  77. Mason AR, Mason J, Cork M, Dooley G, Hancock H. Topical treatments for chronic plaque psoriasis. Cochrane Database of Systematic Reviews 2013; Issue 3. Art. No.: CD005028. https://doi.org/10.1002/14651858.CD005028.pub3.

  78. Reichrath J, Perez A, Müller SM, Chen TC, Kerber A, Bahmer FA, et al. Topical calcitriol (1,25-dihydroxyvitamin D3) treatment of psoriasis: an immunohistological evaluation. Acta Derm Venereol. 1997;77(4):268–72.

    CAS  PubMed  Google Scholar 

  79. van de Kerkhof PCM. An update on topical therapies for mild-moderate psoriasis. Dermatol Clin. 2015;33(1):73–7. https://doi.org/10.1016/j.det.2014.09.006.

    Article  PubMed  Google Scholar 

  80. Prasad V, Chaurasia S. Performance evaluation of non-ionic surfactant based tazarotene encapsulated proniosomal gel for the treatment of psoriasis. Mater Sci Eng C. 2017;79:168–76. https://doi.org/10.1016/j.msec.2017.05.036.

    Article  CAS  Google Scholar 

  81. Koo J, Behnam SE, Behnam SM. The efficacy of topical tazarotene monotherapy and combination therapies in psoriasis. Expert Opin Pharmacother. 2003;4(12):2347–54. https://doi.org/10.1517/14656566.4.12.2347.

    Article  CAS  PubMed  Google Scholar 

  82. Wang C, Lin A. Efficacy of topical calcineurin inhibitors in psoriasis. J Cutan Med Surg. 2014;18(1):8–14. https://doi.org/10.2310/7750.2013.13059.

    CAS  PubMed  Google Scholar 

  83. Lapteva M, Mondon K, Möller M, Gurny R, Kalia YN. Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis. Mol Pharm. 2014;11(9):2989–3001. https://doi.org/10.1021/mp400639e.

    Article  CAS  PubMed  Google Scholar 

  84. Gabriel D, Mugnier T, Courthion H, Kranidioti K, Karagianni N, Denis MC, et al. Improved topical delivery of tacrolimus: a novel composite hydrogel formulation for the treatment of psoriasis. J Control Release. 2016;242:16–24. https://doi.org/10.1016/j.jconrel.2016.09.007.

    Article  CAS  PubMed  Google Scholar 

  85. Wan T, Pan J, Long Y, Yu K, Wang Y, Pan W, et al. Dual roles of TPGS based microemulsion for tacrolimus: enhancing the percutaneous delivery and anti-psoriatic efficacy. Int J Pharm. 2017;528(1–2):511–23. https://doi.org/10.1016/j.ijpharm.2017.06.050.

    Article  CAS  PubMed  Google Scholar 

  86. Paul C, Bang B, Lebwohl M. Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile. Expert Opin Pharmacother. 2017;18(1):1,115–21. https://doi.org/10.1080/14656566.2016.1269749.

    Article  Google Scholar 

  87. Yamauchi P. DFD-01: a novel topical formulation of betamethasone dipropionate for the treatment of extensive psoriasis. Expert Rev Clin Immunol. 2016;13(2):85–91. https://doi.org/10.1080/1744666X.2017.1270756.

    Article  PubMed  Google Scholar 

  88. Efficacy and safety of calcipotriol plus hydrocortisone ointment compared with tacalcitol ointment in patients with psoriasis on the face and skin folds (NCT00640822). https://clinicaltrials.gov/ct2/show/results/NCT00640822?term=NCT00640822 . Updated October 21, 2013.

  89. Kivelevitch DN, et al. Emerging topical treatments for psoriasis. Expert Opin. Emerging Drugs. 2013;18(4).

  90. Rivera AM, Hsu S. Topical halobetasol propionate in the treatment of plaque psoriasis: a review. Am J Clin Dermatol. 2005;6(5):311–6. https://doi.org/10.2165/00128071-200506050-00004.

    Article  PubMed  Google Scholar 

  91. Dermipsor reports good results in DPS-101 Phase IIb study for plaque psoriasis [press release]. Evaluate website. http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=250042. Published October 15, 2007.

  92. Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs. 2009;10(11):1236–42.

    CAS  PubMed  Google Scholar 

  93. Moustafa F, Feldman SR. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J. 2014;20:22608.

    PubMed  Google Scholar 

  94. Product candidates: targeting p-STAT3 for improved psoriasis treatment. Moleculin Web site. http://moleculin.com/product-candidates/mol4239

  95. Paired psoriasis lesion, comparative, study to evaluate MOL4239 in psoriasis (NCT01826201). https://clinicaltrials.gov/ct2/show/results/NCT01826201?term=NCT01826201 .... Updated December 22, 2014.

  96. Roblin D, Yosipovitch G, Boyce B, Robinson J, Sandy J, Mainero V, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol. 2015;95(5):542–8. https://doi.org/10.2340/00015555-2047.

    Article  CAS  PubMed  Google Scholar 

  97. Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013;169(1):137–45. https://doi.org/10.1111/bjd.12266.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Papp KA, Bissonnette R, Gooderham M, Feldman SR, Iversen L, Soung J, et al. Treatment of plaque psoriasis with an ointment formulation of the janus kinase inhibitor, tofacitinib: a phase 2b randomized clinical trial. BMC Dermatol. 2016;16(1):15. https://doi.org/10.1186/s12895-016-0051-4.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Punwani N, Scherle P, Flores R, Shi J, Liang J, Yeleswaram S, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol. 2012;67(4):658–64. https://doi.org/10.1016/j.jaad.2011.12.018.

    Article  CAS  PubMed  Google Scholar 

  100. Rafael A, Torres T. Topical therapy for psoriasis: a promising future, focus on JAK and phosphodiesterase-4 inhibitors. Eur J Dermatol. 2016;26(1):3–8. https://doi.org/10.1684/ejd.2015.2663.

    CAS  PubMed  Google Scholar 

  101. de la Brassinne M, Nikkels A. Psoriasis: state of the art 2013. Acta Clin Belg. 2013;68(6):433–41. https://doi.org/10.2143/ACB.3388.

    Article  PubMed  Google Scholar 

  102. Bissonnette R, Bolduc C, Maari C, Nigen S, Webster JM, Tang L, et al. Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized, double-blind placebo-controlled, phase II trial. J Eur Acad Dermatol Venereol. 2012;26(12):1516–21. https://doi.org/10.1111/j.1468-3083.2011.04332.x.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. VSRC at the Center for Research, Testing and Product Development, 117 C Palanca, Legaspi Village, Makati, Philippines

    Vermén M. Verallo-Rowell & Stephanie S. Katalbas

  2. Institute of Herbal Medicine and Head Skin Study Group, University of the Philippines—National Institutes of Health, Manila, Philippines

    Vermén M. Verallo-Rowell

  3. Skin and Cancer Foundation, Inc., Pasig City, Philippines

    Stephanie S. Katalbas

  4. Levana Dermatology Clinic, Love Your Skin Group of Clinics, Quezon City, Philippines

    Mara Therese P. Evangelista

  5. De La Salle Health Sciences Institute, Cavite, Philippines

    Johannes F. Dayrit

Authors
  1. Vermén M. Verallo-Rowell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephanie S. Katalbas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mara Therese P. Evangelista
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Johannes F. Dayrit
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vermén M. Verallo-Rowell.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Psoriasis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Verallo-Rowell, V.M., Katalbas, S.S., Evangelista, M.T.P. et al. Review Update on Topical Therapy for Psoriasis. Curr Derm Rep 7, 24–36 (2018). https://doi.org/10.1007/s13671-018-0209-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13671-018-0209-x

Keywords

Search

Navigation